(S)-[(2-tert-butoxycarbonylamino-ethylcarbamoyl)phenylmethyl]-carbamic acid benzyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-[(2-tert-butoxycarbonylamino-ethylcarbamoyl)phenylmethyl]-carbamic acid benzyl ester
• 英文别名: benzyl N-[(1S)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]-2-oxo-1-phenylethyl]carbamate
• 化学式: C₂₃H₂₉N₃O₅
• 分子量: 427.5
• InChiKey: PUVIWFXITFQSIE-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-[(2-tert-butoxycarbonylamino-ethylcarbamoyl)phenylmethyl]-carbamic acid benzyl ester 在 盐酸 、 10 wt% Pd(OH)2 on carbon 、 氢气 、 N,N-二异丙基乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 82.0h， 生成 (S)-N-[(2-amino-ethylcarbamoyl)-phenylmethyl]-2-(3,5-bis-trifluoromethylphenyl)-isobutyramide chloride
  参考文献：
  名称：

  Design and synthesis of potential dual NK1/NK3 receptor antagonists

  摘要：

  The tachykinin NK1 and NK3 receptors are a novel drug target for schizophrenia in order to treat not only the positive and cognitive symptoms, but also the associated co-morbid depression and sleep disturbances associated with the disease. A novel class of peptidomimetic derivatives based on a versatile phenylglycine central core was synthesized and tested in vitro as dual NK1/NK3 receptor antagonists. From this series emerged compounds with good NK1 receptor affinity, although only modest dual NK1/NK3 receptor affinity was observed with one of these analogs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.033
• 作为产物：
  描述：

  N-叔丁氧羰基-1,2-乙二胺 、 Cbz-L-苯甘氨酸 在 N,N-二异丙基乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 二氯甲烷 为溶剂， 反应 18.08h， 以60%的产率得到(S)-[(2-tert-butoxycarbonylamino-ethylcarbamoyl)phenylmethyl]-carbamic acid benzyl ester
  参考文献：
  名称：

  Design and synthesis of potential dual NK1/NK3 receptor antagonists

  摘要：

  The tachykinin NK1 and NK3 receptors are a novel drug target for schizophrenia in order to treat not only the positive and cognitive symptoms, but also the associated co-morbid depression and sleep disturbances associated with the disease. A novel class of peptidomimetic derivatives based on a versatile phenylglycine central core was synthesized and tested in vitro as dual NK1/NK3 receptor antagonists. From this series emerged compounds with good NK1 receptor affinity, although only modest dual NK1/NK3 receptor affinity was observed with one of these analogs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.033

文献信息

• Design and synthesis of potential dual NK1/NK3 receptor antagonists
  作者：Stephen Hanessian、Vincent Babonneau、Nicolas Boyer、Clotilde Mannoury la Cour、Mark J. Millan、Guillaume De Nanteuil

  DOI：10.1016/j.bmcl.2013.12.033

  日期：2014.1

  The tachykinin NK1 and NK3 receptors are a novel drug target for schizophrenia in order to treat not only the positive and cognitive symptoms, but also the associated co-morbid depression and sleep disturbances associated with the disease. A novel class of peptidomimetic derivatives based on a versatile phenylglycine central core was synthesized and tested in vitro as dual NK1/NK3 receptor antagonists. From this series emerged compounds with good NK1 receptor affinity, although only modest dual NK1/NK3 receptor affinity was observed with one of these analogs. (C) 2013 Elsevier Ltd. All rights reserved.